Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …

Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different
viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of …

(Background) Lopinavir-ritonavir (LPV/RTV) is a human immunodeficiency virus (HIV)
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …

Deuremidevir hydrobromide tablets and simnotrelvir tablets/ritonavir tablets (co-packaged)
were approved by the Chinese National Medical Products Administration for the treatment of …

Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …

Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major
global health challenge. Till date, no drug has been approved for the treatment of this …